AXSM
Axsome Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$206.94
−0.68%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
1234.7x
EV/EBITDA
−59.7x
Market Cap
$10.84B
MomentumView details →
1D Return
−0.68%
YTD Return
+13.55%
RSI (14)
43.9
ValuationView details →
P/E (Fwd)
1234.7x
EV/EBITDA
−59.7x
Market Cap
$10.84B
RSI (14)
43.9
MomentumView details →
1D Return
−0.68%
YTD Return
+13.55%
SummaryUpdated Jun 1, 2026
Axsome Therapeutics, Inc. (NASDAQ:AXSM) is a biopharmaceutical company founded in 2012 and headquartered in New York. The company went public in 2015 and focuses on developing and commercializing novel therapies for central nervous system (CNS) disorders. Axsome has successfully transitioned from a pure development-stage company to a commercial-stage biopharmaceutical company with multiple approved products generating significant revenue growth.
Similar companies
Latest newsMore news →
Axsome Therapeutics began dosing in the Phase III SUMMIT study of AXS-05 for smoking cessation in adults.3d agoBlackRock Inc. acquired a new minority stake in Axsome Therapeutics, Inc., buying 3,103,708 shares valued at approximately $759.70 million during the second quarter, as disclosed in its 13F filing with the SEC.12d agoAxsome Therapeutics initiated FOCUS-2 and FOCUS-3 Phase 3 trials of solriamfetol in children and adolescents with ADHD.25d ago